bpc-157 safety humans review – No Proof Required! | Office for Science and Society bpc-157 safety human studies review

doi:10.1016/s0944-7113(99)80013-0 Wlbling RH, Leonhardt K

For straightforward wrist injuries, BPC-157 alone usually suffices

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data

CoolSculpting is perfect for people who simply want to reduce stubborn fat areas beneath the chin or on the back of the arms

CONTRAINDICATIONS Sensitivity to cobalt and/or vitamin B12 is a contraindication

[18] also showed no distinct adverse effects of the substance